knowledge -WSS

knowledge

author：focus 2025-10-02 00:28:06 - browse：36

Photo of a doctor holding a cellphone. -- first opinion coverage from STAT — Adobe

Thinking about messaging your physician about a weird rash? You may want to hold off on it. Some hospital systems have started charging patients for digital messages to their doctors via the electronic medical record, either a flat rate (like a copay) or on sliding scale depending on the time or complexity of the physician’s response. Sometimes it’s billed through an insurer, sometimes as a direct cost to the patient. Costs have ranged between less than $10 and $100 for a message.

Now that at least 22 hospital systems have implemented the practice, a great debate has broken out in the medical profession: Is charging patients to send a note to a doctor just common sense or an unjust expense?

In asking family, friends, and colleagues about this, my grandmother’s response was the most enlightening: “I’m surprised doctors ever stopped charging for phone calls!”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Cassava Sciences’ Alzheimer’s clinical trials should be halted

hotspot

WSS

UnitedHealth, Optum discontinue NaviHealth name

Regeneron agrees to White House price limits on anti

How medical schools plan to diversify without affirmative action

Roivant's CEO is a star, but biotech's black hole persists

Is there really a nursing shortage in the U.S.?

Private equity could exacerbate cardiology's overuse problem, experts fear

focus

knowledge

focus

Novavax promises a turnaround & Lilly roils the obesity market

New weight loss drugs vying to be the next Wegovy or Mounjaro

As demand for Covid shots wanes, Moderna seeks its next success

White House touts steps to stem shortages of cancer treatments

New air purifier tech could be key to improving indoor air quality

CZI to create biohub to build anti

Apple is now the first public company to be valued at $3 trillion

Roche drug slashes death risk in early

Cancer drug shortages should be causing more outrage

How medical schools plan to diversify without affirmative action

knowledge

UnitedHealth, Optum discontinue NaviHealth name

FDA clears Verve to begin U.S. study of gene

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Study on Amgen’s bispecific immunotherapy produces positive data

What to make of Biden’s latest efforts on cancer research

Questions loom on AstraZeneca cancer drug as safety concerns ebb

hotspot

explore

hotspot

focus